Bender Robert & Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bender Robert & Associates’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,710	Closed	-$226K	–	41
2026 Q1	$226K	Buy	+23,710	New	+$184K	0.05%	42
2025 Q4	–	Sell	-23,710	Closed	-$180K	–	41
2025 Q3	$180K	Hold	23,710	–	–	0.04%	45
2025 Q2	$212K	Buy	+23,710	New	+$221K	0.05%	44
2025 Q1	–	Sell	-23,710	Closed	-$178K	–	42
2024 Q4	$178K	Buy	+23,710	New	+$180K	0.04%	45
2024 Q1	–	Sell	-56,600	Closed	-$339K	–	44
2023 Q4	$339K	Hold	56,600	–	–	0.09%	40
2023 Q3	$401K	Sell	56,600 -12,000	-17%	-$86.2K	0.12%	39
2023 Q2	$483K	Hold	68,600	–	–	0.13%	39
2023 Q1	$572K	Buy	+68,600	New	+$660K	0.18%	41
2022 Q4	–	Sell	-68,600	Closed	-$864K	–	49
2022 Q3	$864K	Hold	68,600	–	–	0.33%	34
2022 Q2	$726K	Buy	+68,600	New	+$708K	0.28%	36

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Bender Robert & Associates's BCRX Position: Q2 2026 in Review

Bender Robert & Associates sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 23,710 shares — an estimated $226K sold.

Bender Robert & Associates first reported a position in BCRX in Q2 2022 and held it in 10 quarters. The position peaked at $864K in Q3 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Bender Robert & Associates reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Bender Robert & Associates sold 23,710 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $226K.
Bender Robert & Associates first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 10 quarters.
Bender Robert & Associates's BioCryst Pharmaceuticals position peaked at $864K in Q3 2022.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Bender Robert & Associates's 13F filing for Q2 2026, filed 30 Jul 2026.